Condition
Recurrent Uterine Corpus Carcinosarcoma
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
Early P 1 (1)
P 1 (1)
Trial Status
Terminated1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT03120624Phase 1Active Not Recruiting
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
NCT04906382Early Phase 1Terminated
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Showing all 2 trials